Aktuellt
SENASTE
Redeye leaves a comment following Lipum’s announcement of further clinical advancements in the ongoing phase I study with lead candidate SOL-116. We are encouraged to learn that SOL-116 continues to show a favorable safety and tolerability in the multiple dose part of the study. Furthermore, the data confirms the preferred pharmacokinetic profile previously seen in the initial single dose part of the study.
LÄS MER
